Search Results
Your search for ,iII matches 9601 pages
Showing 301 - 350Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to...
Metastatic NSCLC: Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non–small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual ...
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
Romiplostim for Chemotherapy-Induced Thrombocytopenia
In a phase III trial (RECITE) reported in The New England Journal of Medicine, Al-Samkari et al found that the thrombopoietin receptor agonist romiplostim was effective in treating chemotherapy-induced thrombocytopenia (CIT) among patients receiving oxaliplatin-based multiagent cytotoxic...
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. Several weeks ago, when the PA’s fingers moved over the mass visibly protruding...
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
Case 1: RCC With Disease Progression After Adjuvant Pembrolizumab
This is Part 1 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of renal cell carcinoma...
Colorectal Cancer: Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy
The antidepressant duloxetine was unable to prevent sensory oxaliplatin-induced peripheral neuropathy more significantly than placebo in patients with colorectal cancer receiving chemotherapy, according to the results of the Alliance A221805 trial published in JCO Oncology Advances. “Since we know ...
Advanced Prostate Cancer: Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
In a post hoc analysis of the phase III ARCHES and PROSPER trials reported in the Journal of Clinical Oncology, Armstrong et al found that radiographic progression (rPD) often occurred without prostate-specific antigen (PSA) rise in patients with advanced prostate cancer receiving the androgen...
IMPT vs IMRT in Oropharyngeal Cancer
As reported in The Lancet by Thomson et al, the UK phase III TORPEdO trial has shown similar outcomes with intensity-modulated proton therapy (IMPT) vs intensity-modulated radiation therapy (IMRT) in patients with locally advanced oropharyngeal squamous cell carcinoma. Study Details In the...
Metastatic Papillary Renal Cancer: Final Results With Savolitinib and Durvalumab
As reported in the Journal of Clinical Oncology by Jackson-Spence et al, final results of the phase II CALYPSO study indicated better overall survival and other outcomes with savolitinib and durvalumab among patients with metastatic papillary renal cancer who have MET-driven disease. Study...
Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Conflict
A new analysis from Phesi, a data analytics company, of 65,061 globally recruiting clinical trials across 186 countries has found that 4,361 studies—equivalent to 6.7% of all active trials—are impacted by disruption in the Middle East. Across a total of 356,699 recruiting investigator sites, 7,958...
Financial Hardship and Late-Stage Cancer Diagnosis
In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with organized screening programs and those detectable via physical examination. Study Details The...
Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
As reported in The New England Journal of Medicine by Langley et al, a UK phase III trial (PATCH/STAMPEDE-1) has shown noninferiority in metastasis-free survival with the use of transdermal estradiol (tE2) patches vs luteinizing hormone–releasing hormone (LHRH) agonist treatment in men with locally ...
Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment
In a Chinese study reported in the Journal of Clinical Oncology, Huang et al developed a classification for metabolic subtypes of nasopharyngeal carcinoma that may help identify patients benefiting most from the addition of PD-1 inhibition to chemoradiotherapy (CRT) in locoregionally advanced...
Adjuvant Atezolizumab and mFOLFOX6 in Stage III Mismatch Repair–Deficient Colon Cancer
As reported in The New England Journal of Medicine by Sinicrope et al, the phase III ATOMIC trial has shown that the addition of adjuvant atezolizumab to mFOLFOX6 (modified fluorouracil, oxaliplatin, and leucovorin) improved disease-free survival in patients with resected stage III mismatch...
Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery
Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the axilla, by having radiotherapy instead. New findings, presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona, suggest that axillary radiotherapy may be as...
Pembrolizumab With or Without Lenvatinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Licitra et al, the phase III LEAP-010 trial showed an improved objective response rate and progression-free survival—but not overall survival—with the addition of first-line lenvatinib to pembrolizumab in patients with recurrent or metastatic head...
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precursor Asymptomatic Neoplasms by Group Effort Analysis–Smoldering Multiple Myeloma (PANGEA-SMM),...
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
In an interim analysis of a Chinese phase II/III trial (ZSAB) reported in The New England Journal of Medicine, Shi et al found that a neoadjuvant GOLP regimen (gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor [toripalimab]) improved event-free survival vs no neoadjuvant treatment in...
Gedatolisib-Based Regimens in HR-Positive, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer
In a phase III trial (VIKTORIA-1) reported in the Journal of Clinical Oncology, Hurvitz et al found that gedatolisib and fulvestrant both with and without palbociclib improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative, PIK3CA wild-type...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management
ASCO has released a guideline update addressing advances in the use of immunotherapy and targeted therapy for the treatment of advanced gastroesophageal cancer.1 The guideline, last updated in 2023 to include first-line therapy recommendations for patients with biomarkers such as PD-L1 and HER2,...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
On March 20, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma. The FDA also granted traditional...
Hypofractionated Locoregional RT in Early Breast Cancer
As reported in The Lancet by Rivera et al, 5-year results of a French phase III trial (UNICANCER HypoG-01) showed noninferiority of hypofractionated locoregional radiotherapy (RT) vs standard 5-week RT in reducing risk of postsurgery lymphedema in patients with early breast cancer. Study Details In ...
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response...
New AACR President-Elect and Board Members Announced
The members of the American Association for Cancer Research (AACR) have elected Robert H. Vonderheide, MD, DPhil, as the AACR President-elect for 2026–2027. Dr. Vonderheide will become President-Elect on Monday, April 20, during AACR’s Annual Business Meeting of Members at the AACR Annual Meeting...
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients with locally advanced/metastatic urothelial carcinoma. The results from the randomized phase III...
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal Cancers Symposium. Of 41 evaluable patients treated with single-agent...
PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%
A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biopsy, according to first results from the phase III PRIMARY2 trial presented at the 2026 Annual...
Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
As reported in JAMA Oncology by Yang et al, the 3-year follow-up of the predominantly Chinese phase III RATIONALE-309 trial showed a maintained progression-free survival benefit with the addition of first-line tislelizumab to chemotherapy in patients with recurrent or metastatic nasopharyngeal...
Forgotten Lessons From South Africa
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New...
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine. “This work has been nearly a decade in the making, and it is so important because there are no available...
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
In a Chinese phase III trial (CAMPASS) reported in The Lancet Oncology, Zhong et al found that the PD-L1 inhibitor benmelstobart plus the tyrosine kinase inhibitor anlotinib significantly improved progression-free survival vs placebo plus pembrolizumab in the first-line treatment of PD-L1–positive...
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response after surgical resection or local ablation, based on the phase III KEYNOTE-937 trial.1 Presented at...
Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence
Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrence following a nephrectomy. Now, results from the phase III LITESPARK-022 study investigating the...
Disease Stage at Breast Cancer Diagnosis Impacted by Region, Race, and Insurance
Significant differences were found in advanced-stage diagnoses of breast cancer in rural populations according to geographic location in the United States, which were further influenced by demographic factors of race and insurance status, according to findings from an analysis of the National...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
Stanford Names Leader for Drug Development and Precision Oncology
Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In this role, he will lead the Early Drug Development Program to expand access to innovative treatments...
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
In a European phase II/III trial (AXINET) reported in the Journal of Clinical Oncology, Garcia-Carbonero et al found that the addition of axitinib to long-acting octreotide appeared to show activity in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). Study Details The...
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1 “Mandatory and uniform reporting of all [venous and arterial...
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
As reported in the Journal of Clinical Oncology by Scherpereel et al, 5-year findings from the phase III CheckMate 743 trial showed continued overall survival benefit of first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectable pleural mesothelioma. Study Details In the...
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.1 Of 41 evaluable patients treated with...
Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and Pembrolizumab
Matthew D. Galsky, MD, FASCO, of Mount Sinai Tisch Cancer Center, discusses findings from the randomized phase III KEYNOTE-B15/EV-304 study, which is evaluating neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab followed by radical cystectomy plus pelvic lymph node dissection vs...
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfortumab vedotin plus pembrolizumab to radical cystectomy in patients with muscle-invasive bladder...
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
In an individual patient data meta-analysis reported at the 2026 ASCO Genitourinary Cancers Symposium (Abstract 305) and simultaneously published in The Lancet, Kishan et al found no apparent overall survival benefit of adding hormone therapy in patients undergoing postoperative radiotherapy after...
Fifteen-Year Results From SWOG S0016 Suggest Follicular Lymphoma May Be Curable
Advanced-stage follicular lymphoma is currently considered incurable. But a new analysis of long-term data from patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered...
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
Based on the results from the phase III KEYNOTE-564 study, adjuvant pembrolizumab is currently standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence following a nephrectomy. Now, the results from the phase III LITESPARK-022 study—which investigated the...
